Literature DB >> 17194825

Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

Russell E Lewis1, Georgios Chamilos, Randall A Prince, Dimitrios P Kontoyiannis.   

Abstract

In a nonneutropenic murine model of invasive pulmonary aspergillosis, pretreatment with empty liposomes (E-lipo) was nearly as effective as 10 mg/kg of body weight liposomal amphotericin B and superior to 1 mg/kg amphotericin B deoxycholate. The beneficial immunomodulatory properties of E-lipo appear to compensate for their lack of direct antifungal activity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17194825      PMCID： PMC1803112          DOI： 10.1128/AAC.01268-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

Review 3.  Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil.

Authors:  M Rao; C R Alving
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

4.  Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia.

Authors:  D F Eierman; M Yagami; S M Erme; S R Minchey; P A Harmon; K J Pratt; A S Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Antifungal activity of human polymorphonuclear and mononuclear phagocytes against non-fumigatus Aspergillus species.

Authors:  O Akpogheneta; C Gil-Lamaignere; A Maloukou; E Roilides
Journal:  Mycoses       Date:  2003-04       Impact factor: 4.377

6.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

7.  Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus.

Authors:  Yasuhiro Tsuda; Hitoshi Takahashi; Makiko Kobayashi; Toshiaki Hanafusa; David N Herndon; Fujio Suzuki
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

8.  Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation.

Authors:  Andrew BitMansour; Janice M Y Brown
Journal:  J Infect Dis       Date:  2002-06-10       Impact factor: 5.226

9.  Toll-like receptors stimulate human neutrophil function.

Authors:  Fumitaka Hayashi; Terry K Means; Andrew D Luster
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

Review 10.  The damage-response framework of microbial pathogenesis.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Nat Rev Microbiol       Date:  2003-10       Impact factor: 60.633
View more
  16 in total

Review 1.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

2.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

3.  Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx?

Authors:  Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2014-02-25       Impact factor: 5.882

Review 4.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

5.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

6.  Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.

Authors:  Hsin-Yun Sun; Barbara D Alexander; Olivier Lortholary; Francoise Dromer; Graeme N Forrest; G Marshall Lyon; Jyoti Somani; Krishan L Gupta; Ramon del Busto; Timothy L Pruett; Costi D Sifri; Ajit P Limaye; George T John; Goran B Klintmalm; Kenneth Pursell; Valentina Stosor; Michelle I Morris; Lorraine A Dowdy; Patricia Munoz; Andre C Kalil; Julia Garcia-Diaz; Susan Orloff; Andrew A House; Sally Houston; Dannah Wray; Shirish Huprikar; Leonard B Johnson; Atul Humar; Raymund R Razonable; Shahid Husain; Nina Singh
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

7.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

8.  Combination echinocandin-polyene treatment of murine mucormycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Yue Fu; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

9.  Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

Authors:  T M Hohl; M Feldmesser; D S Perlin; E G Pamer
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

10.  Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.

Authors:  Gregory A Lamaris; Russell E Lewis; Georgios Chamilos; Gregory S May; Amar Safdar; Thomas J Walsh; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.